Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
PZ HTL SA

New Program Aids Physicians Identify Gene-Drug Interactions

By BiotechDaily International staff writers
Posted on 23 Apr 2013
A data management and analysis platform gives doctors real-time therapeutic and diagnostic guidance, based on the patient’s genetic profile.

Developed by researchers at Mount Sinai Medical Center (MSMC; New York, NY, USA), the revolutionary platform communicates with the MSMC electronic health record (EHR). MSMC is pilot testing the platform through the CLinical Implementation of Personalized Medicine through Electronic health Records and Genomics (CLIPMERGE) research program. Once a patient has consented to take part in CLIPMERGE, their DNA is analyzed for genetic variations, which are stored on the platform, and remain there until the patient is prescribed a medication for which CLIPMERGE holds genomically relevant information.

Such information could include a lower likelihood of the drug being effective, or there being a higher chance of side effects due to that patient’s particular type of genetic variation. When this happens, CLIPMERGE displays an alert on the EHR screen and sends a message, in real time, to the attending physician, consisting of text describing the reason for the alert, some suggestions of alternative medications or doses that could be used, and a link to reference material so that physicians can read more about the science and evidence for pharmacogenomics. A study describing CLIPMERGE will be published in the August 2013 issue of Clinical Pharmacology and Therapeutics.

“Our knowledge of pharmacogenomics, or genome-drug interactions, and how genetics can influence why some patients react better to some drugs than others, is growing rapidly, and will likely transform how drugs are prescribed in the future,” said lead author Omri Gottesman, MD. “We hope that through CLIPMERGE, we can establish best practices both technological and human; and a robust process for clinical-decision support to deliver relevant genomic information to physicians at the moment they are caring for patients.”

Beyond the 1,500 patients enrolled in the pilot project, Mount Sinai has also enrolled since 2007 a total of 25,000 patients in the BioMe Biobank, one of the largest genetic repositories in the United States. The combination of BioMe and CLIPMERGE allows feedback on optimal therapeutics for multiple conditions related to cardiovascular disease, blood clots, high cholesterol, depression, and pain, based on a patient’s DNA, and is an important step forward on the road to personalized medicine.

“Enrolling this number of patients is a significant achievement for Mount Sinai and combined with programs such as CLIPMERGE, is propelling us to the forefront of precision medicine and its application in the clinical setting,” said Dennis Charney, MD, executive vice president for academic affairs of The MSMC. “The future of medicine lies in genomics research and translating it to the bedside—and Mount Sinai’s commitment to translational research makes us uniquely poised to lead that revolution.”

Related Links:

Mount Sinai Medical Center





comments powered by Disqus

Channels

Genomics/Proteomics

view channel

New Program Encourages Wide Distribution of Genomic Data

A new data sharing program allows genomics researchers and practitioners to analyze, visualize, and share raw sequence data for individual patients or across populations straight from a local browser. The sequencing revolution is providing the raw data required to identify the genetic variants underlying rare diseases... Read more

Drug Discovery

view channel
Image: The nano-cocoon drug delivery system is biocompatible, specifically targets cancer cells, can carry a large drug load, and releases the drugs very quickly once inside the cancer cell. Ligands on the surface of the \"cocoon\" trick cancer cells into consuming it. Enzymes (the “worms\" in this image) inside the cocoon are unleashed once inside the cell, destroying the cocoon and releasing anticancer drugs into the cell (Photo courtesy of Dr. Zhen Gu, North Carolina State University).

Novel Anticancer Drug Delivery System Utilizes DNA-Based Nanocapsules

A novel DNA-based drug delivery system minimizes damage to normal tissues by utilizing the acidic microenvironment inside cancer cells to trigger the directed release of the anticancer drug doxorubicin (DOX).... Read more

Lab Technologies

view channel

Experimental Physicists Find Clues into How Radiotherapy Kills Cancer Cells

A new discovery in experimental physics has implications for a better determination of the process in which radiotherapy destroys cancer cells. Dr. Jason Greenwood from Queen’s University Belfast (Ireland) Center for Plasma Physics collaborated with scientists from Italy and Spain on the work on electrons, and published... Read more

Business

view channel

Interest in Commercial Applications for Proteomics Continues to Grow

Increasing interest in the field of proteomics has led to a series of agreements between private proteomic companies and academic institutions as well as deals between pharmaceutical companies and novel proteomics innovator biotech companies. Proteomics is the study of the structure and function of proteins.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.